Navigation Links
Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial
Date:4/12/2011

ression, which were resolved via dose adjustment in two cases and discontinuance in the third. One patient experienced a pulmonary embolism 19 days post-surgery secondary to an iliac vein thrombosis, unlikely related to the cells. All adverse events were resolved. In the group of ambulatory patients, all three remain ambulatory and experienced no serious adverse events secondary to surgery.  

"It has been 15-to-4 months since the first nine patients have received the cells," said Karl Johe, Ph.D., Chief Scientific Officer and Chairman of Neuralstem's Board of Directors.  "There have been no adverse reactions possibly or probably or definitely related to the cells.  This indicates that the trial is proceeding as smoothly as can be hoped for. It is designed for transplantation to progress up to the cervical region of spinal cord as safety is demonstrated in the lumbar region," Dr. Johe continued. "With SMB and FDA review of the safety data from the 12 patients due to be completed in the next month, we hope to begin transplanting ALS patients in the cervical region this summer."

"This is significant and, we believe, compelling safety data," said Richard Garr president and CEO of Neuralstem. "It represents the first safety results from the world's first ALS neural stem cell trial, as well as the first data from Neuralstem's ongoing clinical programs. We believe it also validates our proprietary Spinal Injection Platform for the safe intraspinal delivery of our cells.  We  remain deeply indebted to the patients and their families who are participating in the study."

About the Study

Safety results were presented on nine patients in an ongoing Phase I study to evaluate the safety of Neuralstem's spinal cord stem cells (HSSC's), as well as the transplantation technique, in the treatment of ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).

Of these nine patients, the first six (Cohort A) were a
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial
2. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
3. /C O R R E C T I O N -- Prof Terje Pedersen, SEAS Study Principal Investigator & Head of Steering Committee/
4. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
5. Par Pharmaceutical Announces Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010
6. Secure eHealth, LLC Engages as a Consultant GSI Health Whose Principal and CEO is the Former Senior Advisor to National Coordinator for Health Information Technology
7. Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note
8. International Merchant Advisors Reaches Agreement in Principal to Acquire First Medical Marijuana Clinic Operations
9. NeoStem Announces Warrant Exercise by Principal Shareholder
10. Pascal Metrics Welcomes Jim Conway to Leadership Team as Principal
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 Regado Biosciences, Inc. ... on the Phase 3 clinical development of Revolixys™ Kit ... drug system, today announced that it will hold a ... 12, 2014, at 8:30 a.m. EDT to discuss its ... Interested participants and investors may access the conference ...
(Date:7/29/2014)... 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... healthcare conferences during the third quarter, the 2014 Avondale ... Healthcare 2014 Conference.  Alexza,s corporate presentation will be webcast ... each event are below: , 2014 Avondale ... Boston , MA.  The format is ...
(Date:7/29/2014)... July 29, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... for the fiscal third quarter 2014 after the market ... The Company will host a conference call for investors ... Time (10 a.m. Eastern Time). Investors may access the ...
Breaking Medicine Technology:Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2
... , MIAMI , July 21 Understanding ... patient resources. That,s why Puerto Rican actress, author and mother ... partnered with the Asthma and Allergy Foundation of America (AAFA) ... new Spanish asthma education web resource to help patients learn ...
... Trinity Orthopedics LLC, a medical device company that develops and markets ... a Notice of Allowance from the U.S. Patent and Trademark Office for ... posterior fixation system in the United States under the ReStor ... "Recent clinical studies ...
Cached Medicine Technology:Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 2Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 3Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 4Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 5Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 6Trinity Orthopedics Receives Patent Allowance for Sagittally Stable Spinal Fixation System 2
(Date:7/29/2014)... July 29, 2014 New high priced ... Part D by a projected $2.9 to $5.8 billion ... actuarial firm Milliman released today by the Pharmaceutical Care ... premiums could increase by as much as 8.6 percent ... drugs, including Sovaldi and Olysio. , The study finds ...
(Date:7/29/2014)... By Dennis Thompson ... -- Exercise, a healthy diet and good sleep can protect ... down the aging process at a cellular level, researchers report. ... stressful events are linked to increased shortening of telomeres, the ... quickly cells age. "We found that over a one-year ...
(Date:7/29/2014)... 2014 During his 37 years in dental ... Associates, has had a steady stream of college students shadow ... have now gone on to dental school and some are ... shadowing program helps college students find success. , For students ... them the chance to see a realistic view of what ...
(Date:7/29/2014)... Medicine researchers have made an important advancement toward ... deadly tick-transmitted disease, human granulocytic anaplasmosis (HGA). , ... a steady rise in the incidence of human ... the need for a vaccine critical. Successful vaccine ... prevent disease, and the VCU team has identified ...
(Date:7/29/2014)... Boise, Idaho (PRWEB) July 29, 2014 ... & Hart LLP ’s Boise office, has been appointed ... Cross of Greater Idaho. , Busacker is an experienced ... executive compensation matters. He advises clients on a wide ... plan design, plan administration, compliance, and governance concerns. His ...
Breaking Medicine News(10 mins):Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 2Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 3Health News:Arthur Bruce Dental Helps College Students 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 3Health News:Holland & Hart Partner Brett Busacker Appointed to Board of Directors for American Red Cross of Greater Idaho 2
... (cell culture) research currently underway at the Peninsula Medical School ... and develop therapies for the treatment of multiple tumours in ... a protein called merlin, which in turn cause cancers in ... brain. Schwann cells produce the sheaths that surround and insulate ...
... Makes First Investment in Antibacterial Therapeutics From ... its Biodefense and Pandemic ... today,announced the close of a $30 million Series B financing ... now completing Phase I testing. The financing was led by ...
... Group Calls for Funding Suspension After Trial ... a Baltimore Sun,opinion piece today ( http://www.baltimoresun.com/news/opinion/oped/bal ... suspension of costly HIV vaccine research funding ... proven HIV/AIDS prevention,testing and treatment strategies., ...
... take their lives in the spring, doctors say , , SUNDAY, March ... time of renewal and hope, the greatest number of suicides in ... the American College of Emergency Physicians. , It,s not clear why ... L. Lawrence. But "we do know that suicide is the 11th ...
... Music therapy can help reduce anxiety and improve physical ... everyone has used music at one time or another ... discipline of music therapy takes the use of music ... "Music therapy is an evidence-based practice that can affect ...
... YORK, March 21 Americans with ... their Medicare Advantage Plan have an ... to this report from UnitedHealthcare at:, ... access video, audio, text, graphics and,photos ...
Cached Medicine News:Health News:Research to lead to brain tumor therapies 2Health News:Research to lead to brain tumor therapies 3Health News:Trius Raises $30 Million in Series B Financing 2Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 2Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 3Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 4Health News:Know Suicide's Warning Signs 2Health News:Know Suicide's Warning Signs 3Health News:Music as Medicine 2Health News:Music as Medicine 3
Bi-phasic peristaltic infusion pump for tumescent work....
... a compact system featuring,easy setup and flow ... allowing the use of less,expensive disposable tubing ... office or hospital use, the,PSI-TEC III Infiltrator ... - 5" (w) X 8" (l) X ...
... represents a major advance in the ... procedures. Combined with precision fluid management, ... solid grooved probe design and patented ... been designed to minimize trauma to ...
Inquire...
Medicine Products: